ABL Bio has signed a technology export agreement with GlaxoSmithKline (GSK) to develop new treatments for degenerative brain diseases using the Blood-Brain Barrier (BBB) shuttle platform ‘Grabody-B’. The deal is worth up to 4.1 trillion won, including an upfront payment of 73.9 billion won and short-term milestone payments of 148 billion won. ABL Bio will also receive up to 3.9623 trillion won for development, authorization, and commercialization milestones across multiple programs, and will transfer technology and know-how related to Grabody-B to GSK.
Original Article: Read More
Auto-posted at: 2025-04-07 09:02:28